Clinical Trials on Refractory Neuroblastoma

Total 3256 results

Children's Cancer and Leukaemia Group

Unknown

Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma

Neuroblastoma
University of Vermont
St. Louis University

Completed

Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Texas Children's Cancer Center

Completed

Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma

Neuroblastoma

United States
National Center for Research Resources (NCRR)

Unknown

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

Neuroblastoma

United States
The First Affiliated Hospital of Xiamen University

Recruiting

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

Refractory Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

China
NeoImmuneTech

Recruiting

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

United States
Curis, Inc.
The Leukemia and Lymphoma Society

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditions

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Relapsed Adult AML | Refractory AML

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
M.D. Anderson Cancer Center

Completed

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

Acute Myeloid Leukemia | Myeloproliferative Disorders | Chronic Myelomonocytic Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Shenzhen Core Medical Technology CO.,LTD.

Not yet recruiting

Corheart 6 VAS Study

Refractory Heart Failure

Germany
Imperial College London
Medical Research Council; Imperial College Healthcare Nissen Fund

Recruiting

Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance (ORBITA-COSMIC)

Refractory Angina

United Kingdom
Justin Parker Neurological Institute

Completed

Prospective Randomized Feasibility Study Comparing Manual vs. Automatic Position-Adaptive Spinal Cord Stimulation With Surgical Leads (RestoreSensor)

Chronic Refractory Low Back and Leg Pain

United States
All India Institute of Medical Sciences, New Delhi
Council of Scientific and Industrial Research, India

Completed

Modified Atkins Diet in Childhood Epilepsy (mAD)

Refractory Childhood Epilepsy

India
National University Hospital, Singapore

Unknown

Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma

Advanced Glaucoma | Refractory Glaucoma

Singapore
Seattle Children's Hospital
Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics...

Completed

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

AML | Acute Leukemia of Ambiguous Lineage | ALL | Relapsed/Refractory AML | Relapsed/Refractory ALL | Secondary AML/MDS

United States, Canada
New York Medical College

Terminated

ODSH + ICE Chemotherapy in Pediatric Solid Tumors

Sarcoma | Neuroblastoma | Wilms' Tumor | Refractory Solid Tumor | Recurrent Solid Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditions

United States
Massachusetts General Hospital
National Cancer Institute (NCI)

Recruiting

Phase II Study of Proton Radiation Therapy for Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma

United States
Children's Mercy Hospital Kansas City
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma (STALLONe)

Neuroblastoma

United States
TCRx Therapeutics Co.Ltd

Recruiting

KSH01-TCRT Solid Tumors (KSH01-TCRT)

Refractory Solid Tumors | Relapsed Solid Tumors | TCR-T Cells

China
National Cancer Institute (NCI)

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid Tumor

United States
Hutchmed

Completed

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

Relapsed or Refractory Lymphoma

United States
Eisai Inc.

Terminated

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Refractory Partial Onset Seizures

United States
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditions

United States
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
Narendranath Epperla

Not yet recruiting

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Anemia With Excess Blasts

United States
National Cancer Institute (NCI)

Active, not recruiting

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Ewing Sarcoma | Recurrent Alveolar Rhabdomyosarcoma | Refractory Alveolar Rhabdomyosarcoma

United States, Canada
National Cancer Institute (NCI)

Completed

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Refractory Differentiated Thyroid Gland Carcinoma | Unresectable Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

United States, Canada
Liqun Zou

Recruiting

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Leukemia

China
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Recruiting

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Myelodysplastic Syndromes | AML, Adult | ALL, Adult | CLL, Refractory | CML, Refractory

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Sun Yat-sen University
Hainan General Hospital

Recruiting

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Neuroblastoma

China
University College, London

Not yet recruiting

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma (MAGNETO)

Neuroblastoma
Power Life Sciences Inc.

Not yet recruiting

Determining Patterns In Study Experiences of Neuroblastoma Patients

Neuroblastoma

United States
Novartis Pharmaceuticals
Innovative Therapies For Children with Cancer Consortium

Recruiting

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Neuroblastoma

Germany, Italy, Singapore, Spain, United States, Australia, France
Children's Hospital Los Angeles
United Therapeutics

Recruiting

Rapid Administration Pilot for Infusing Dinutuximab (RAPID)

Neuroblastoma

United States
Centre de recherche du Centre hospitalier universitaire...

Recruiting

68Ga-DOTATATE Neuroblastoma Imaging Pilot

Neuroblastoma

Canada
Giselle Sholler
Beat NB Cancer Foundation; K C Pharmaceuticals Inc.; Team Parker for Life

Recruiting

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Neuroblastoma

United States, Canada
Y-mAbs Therapeutics

Recruiting

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Neuroblastoma

Spain, Denmark, United States, Italy, United Kingdom, Germany, Hong Kong, Canada, France
Giselle Sholler
Beat NB Cancer Foundation; Team Parker for Life

Recruiting

Neuroblastoma Maintenance Therapy Trial (NMTT)

Neuroblastoma

United States, Canada
Giselle Sholler
Beat NB Cancer Foundation; K C Pharmaceuticals Inc.; Team Parker for Life; Dell...

Recruiting

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)

Neuroblastoma

United States, Canada

Clinical Trials on Refractory Neuroblastoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations